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Variable Change from enrollment to visit with progressive
impairment (N¼237)
Change from enrollment to last visit without
impairment (N¼130)
p-value
N Median Mean Min Max N Median Mean Min Max
MD 0-3* 233 0 -0.15 -3 2 128 0 -0.59 -3 1 <0.001
MD 0-10** 232 -1 -0.64 -8 6 128 -2 -1.98 -8 2 <0.001
PT 0-3* 179 0 -0.01 -2 2 59 -1 -0.58 -2 1 <0.001
PT 0-10** 176 0 -0.37 -7 6 63 -2 -1.62 -6 3 <0.001
FACT-BMT 180 -0.92 0 -44.67 54.67 60 13 15 -24.33 45.94 <0.001
Lee symptom summary 190 -0.27 -0.46 -45.22 33.57 63 -6.05 -7.59 -38.81 10.85 <0.001
FACT-BMT ¼ functional assessment of cancer therapy, bone marrow transplant
*Clinician (MD) or Patient (PT)-rated overall chronic GVHD severity on a 0-3 scale (none, mild, moderate, severe)
**MD or PT-rated overall chronic GVHD severity on a 0-10 scale
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Purpose: Graft-versus-host-disease (GVHD) affects more
than 50% of transplanted patients and is a major obstacle to
successful allogeneic stem cell transplantation (alloSCT).
Cannabidiol (CBD), a non-psychotropic ingredient of
Cannabis has been shown to exhibit potent anti-inﬂamma-
tory properties in animal models of various autoimmune
diseases like multiple sclerosis, rheumatoid arthritis, in-
ﬂammatory bowel disease and diabetes mellitus. We hy-
pothesized that the addition of CBD to standard GVHD
prophylaxis may decrease GVHD incidence and severity.Figure 1Patients and Methods:We conducted a prospective phase I/
II study (NCT01385124). Patients were given oral CBD 300
mg/day from day -7 through day +30 plus standard
GVHD immunoprophylaxis consisting of cyclosporine and
methotrexate.
Results: Forty-eight consecutive adult patients undergoing
alloSCT were enrolled. Thirty-eight patients (79%) had acute
leukemia or MDS and 13 patients (27%) had progressive
disease. Thirty-ﬁve patients (73%) were given a myeloa-
blative conditioning. The donor was either an HLA identical
sibling (n¼28), a 10/10 matched unrelated donor (n¼16) or a
1-antigen mismatched unrelated donor (n¼4). Median
follow-up was 16 (range, 7-23) months. There were no grade
3-4 toxicities attributed to CBD. The cumulative incidences of
grade 2-4 and grade 3-4 acute GVHD by day 100 were 12%
and 5%, respectively. None of the patients developed acute
GVHD while consuming CBD. Compared to 101 historical
control subjects given standard GVHD prophylaxis, the haz-
ard ratio of developing grade 2-4 acute GVHD among sub-
jects treated with CBD plus standard GVHD prophylaxis was
0.3 (95% CI: 0.2-0.6; p¼0.0002). The cumulative incidence
of moderate-to-severe chronic GVHD at 1 year was 20%.
Relapse rate, non-relapse mortality and overall survival at 1
year were 41%, 11.1% and 68%, respectively.
Conclusions: The combination of CBD with standard GVHD
prophylaxis is a safe and promising strategy to reduce the.
Figure 1. Morphology of m-CRIECs cultured in CRC medium, RPMI, and RPMI on nanoﬁbrous mesh for 7 days to evaluate morphology and viability. Loss of cobble
stone morphology (black arrow) was observed in cultures without nanoﬁbrous mesh.
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controlled study is warranted.
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Gastrointestinal GVHD is a major complication of alloge-
neic blood and marrow transplantation. In vitro models
for screening potential donor T cell reactivity to host
intestinal epithelial cells (IEC) as a portent of GVHD have
been hampered by difﬁculty in maintaining primary
IEC cultures. To approach this problem, conditional
reprogramming (CR) technology was combined with tis-
sue-engineering scaffolds composed of biocompatible
polycaprolactone (PCL)/collagen nanoﬁbers to enable a
long-term preservation of primary murine IECs. Condi-
tioned medium (CM) used for CR contains the Rho-asso-
ciated kinase inhibitor Y-27632, an anti-apoptotic agent
that can render CRIEC unsuitable for cell damage assays
indicative of GVHD. Thus, we sought to create an enablingbiomimetic extracellular matrix (ECM) platform that could
support viable and functional CR murine-IEC (m-CRIEC) in
the absence of Y-27632.
Methods: Small intestine-derived IEC were plated on ﬁbro-
nectin-coated coverslips with CM+Y-27632. The m-CRIEC
were removed from this media and seeded onto nanoﬁbrous
matrices in the presence of RPMI-1640 media. IEC normally
reside on the thin ﬁbrous basement membrane (BaMe)
consisting of intermingled networks of laminins and type IV
collagen, which provides cell anchoring and barrier func-
tions. The BaMe interacts with cells through integrin re-
ceptors and other plasma membrane molecules, inﬂuencing
cell phenotype and survival. Using electrospinning, BaMe-
like ﬁbrous meshes were prepared. Slow degradable PCL was
used as the ﬁber matrix phase in which Type I collagen
(representing ECM molecules) was dispersed.
Results: Flow cytometric analysis and microscopic inspec-
tion of m-CRIEC growing  7 days under CM+Y-27632-
depleted conditions presented with comparable viability and
phenotypic display to that of m-CRIEC growing in CM+Y-
27632; however only cells placed on nanoﬁbers maintained
cobblestone morphology and integrity (Figure 1).
Conclusions: We have demonstrated that nanoﬁbrous
meshes can provide a physiologically relevant ECM-like
microenvironment for the ex vivo maintenance of IEC. This
biomimetic approach should prove particularly beneﬁcial for
the assessment of intestinal GVHD potential elicited by
donor T cells.
